Skip to content

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Amgen logo
AmgenAMGN
0.6×0.0×
Incyte logo
IncyteINCY
0.0×
AbbVie logo
AbbVieABBV
0.5×0.0×
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
0.0×

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0.0×
Current ratio17.8×+0.5×

Where this comes from

Calculated from Protagonist Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's debt-to-assets?
Protagonist Therapeutics (PTGX) reported debt-to-assets of 0× in Q1 2026.
How has Protagonist Therapeutics's debt-to-assets changed year-over-year?
Protagonist Therapeutics's debt-to-assets decreased by 8.5% year-over-year, from 0× to 0×.
What is the long-term trend for Protagonist Therapeutics's debt-to-assets?
Over 5 years (2020 to 2025), Protagonist Therapeutics's debt-to-assets has grown at a -3.5% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.